Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and marketing treatments for individuals suffering from rare and chronic neuromuscular and neurological disorders in the United States. The financial data pertains to the fiscal year 2025. The company reported an income before tax of $283,515,000.00 showcasing its pre-tax profitability. Catalyst Pharmaceuticals specializes in offering Firdapse, an amifampridine phosphate tablet designed specifically for patients with Lambert-Eaton Myasthenic Syndrome (LEMS), as well as Ruzurgi, which addresses the needs of pediatric LEMS patients. Furthermore, the company is advancing Firdapse for the treatment of myasthenia gravis with MuSK antibodies and spinal muscular atrophy type 3, alongside efforts to address hereditary neuropathy with liability to pressure palsies. The company's stock is identified with the symbol 'CPRX' in the market. Additionally, it recorded a notable revenue of $588,989,000.00 showcasing its steady growth, while the cost of revenue for the company is $87,253,000.00 illustrating its production and operational expenses. Catalyst Pharmaceuticals has entered into license agreements with BioMarin Pharmaceutical Inc., as well as a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Formerly known as Catalyst Pharmaceutical Partners, Inc., the company rebranded as Catalyst Pharmaceuticals, Inc. in May 2015 and has been based in Coral Gables, Florida since its founding in 2002. In the investment landscape, the stock is affordable at $19.78 suitable for budget-conscious investors. With an average trading volume of 1,224,169.00 the stock indicates moderate liquidity, making it accessible to a range of investors. Catalyst Pharmaceuticals operates within a mid-range market capitalization of $2,876,149,739.00 positioning the company as a steady performer in the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. As a member of the Healthcare sector, Catalyst Pharmaceuticals is actively driving innovation and growth, enhancing its reputation and influence in the biopharmaceutical arena.